Navigation Links
Alfacell Reports Financial Results for First Quarter of Fiscal 2009
Date:12/10/2008

SOMERSET, N.J., Dec. 10 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today reported its financial results for the first quarter of fiscal 2009.

The company recorded a net loss of approximately $2.8 million, or $0.06 per basic and diluted common share, for the fiscal quarter ended Oct. 31., compared to a net loss of $2.7 million, or $0.06 per basic and diluted common share, for the first quarter of fiscal 2008. Research and development expenses increased by approximately $0.1 million and were offset by decreases in general and administrative expenses and investment income during the first quarter of fiscal 2009 as compared to the same quarter a year ago.

Cash and Liquidity

As of Oct. 31, the company had cash and cash equivalents of approximately $2.0 million, a decrease of approximately $2.7 million, compared to cash and cash equivalents of approximately $4.7 million on July 31, 2008. In addition to its cash reserves on Oct. 31, the company received proceeds of approximately $1.1 million from the sale of its state tax loss carryforwards in New Jersey in December 2008. Based on the current expected level of expenditures, the company believes that its cash reserves are sufficient to support its activities into the fourth quarter of fiscal year 2009.

Clinical/Regulatory Update

Alfacell has completed a confirmatory Phase IIIb clinical trial for ONCONASE in patients suffering from unresectable malignant mesothelioma (UMM) and reached the required number of evaluable events to conduct the formal statistical analyses required to complete the final sections of the ONCONASE(R) rolling New Drug Application (NDA). As the company has previously reported, the results of the preliminary statistical analysis of the data did not meet statistical significance for the primary endpoint of survival in UMM. However, a statistically significant improvement in survival was seen in the treatment of UMM patients who failed one prior chemotherapy regimen, a pre-defined primary data set for this sub-group of patients in the trial, which represents a currently unmet medical need. Alfacell has been granted a pre-NDA meeting with the Food and Drug Administration (FDA) at the end of January 2009 to discuss the details of the planned NDA submission.

About ONCONASE(R)

ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa Pharmaceuticals, a division of Par Pharmaceutical, Inc. Strategic marketing and distribution agreements for ONCONASE have been secured with Megapharm Ltd. for Israel, BL&H Co. Ltd. for Korea, Taiwan and Hong Kong, USP Pharma Spolka Z.O.O., an affiliate of US Pharmacia, for Eastern Europe, and GENESIS Pharma, S.A. for Southeastern Europe.

ONCONASE has been granted fast track status and orphan-drug designation for the treatment of malignant mesothelioma by the FDA. Additionally, ONCONASE has been granted orphan-drug designation in the European Union and Australia.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. For more information, visit www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainty whether the clinical trial results will allow the company to complete submission of a New Drug Application and if a New Drug Application submission is completed, uncertainty whether FDA will file or approve such application, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials or differences of opinion in interpreting the results of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

    Media Contact:
    David Schull or Wendy Lau
    Russo Partners
    212-845-4271
    David.Schull@russopartnersllc.com
    Wendy.Lau@russopartnersllc.com

    Investor Contact:
    Andreas Marathovouniotis
    Russo Partners
    212-845-4253
    Andreas.Marathis@russopartnersllc.com

                              ALFACELL CORPORATION

                       Condensed Statements of Operations

                                  (Unaudited)

                                                   Three-Months Ended
                                                       October 31
                                                  2008            2007

      Revenues                               $          -   $          -

      Expenses:
       Research and development                 1,727,381      1,615,791
       General and administrative               1,093,473      1,171,516
         Total expenses                         2,820,854      2,787,307

       Loss from operations                    (2,820,854)    (2,787,307)

    Interest income, net                           17,451         60,507

      State tax benefit                                 -              -

      Net loss                               $ (2,803,403)  $ (2,726,800)

      Net loss per common share-basic and
       diluted                               $      (0.06)  $      (0.06)

      Shares used in computation of net loss
       per common share:
         Basic and diluted                     46,310,500     44,430,000


                                Balance Sheet Data:

                                        October 31,        July 31,
                                          2008              2008

     Cash and cash equivalents      $     1,959,146    $    4,661,656
     Total assets                   $     2,671,681    $    5,320,036
     Current liabilities            $     2,453,854    $    2,882,034
     Accumulated deficit            $  (107,196,259)   $ (104,392,856)
     Total stockholders' deficiency $    (5,713,515)   $   (3,556,606)




'/>"/>
SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alfacell to Host Fiscal First Quarter 2008 Financial Results Conference Call and Webcast
2. Sinobiopharma Reports Highlights of Third Quarter Results for Its Operating Subsidiary, Dong Ying China
3. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
4. Winner Medical Reports Fourth Quarter and Full Year Fiscal 2008 Results
5. Morpace Reports: Many Likely to Create Own Online Personal Medical Record
6. MIB Life Index Reports North American Life Insurance Activity Off 1.9% in November
7. Health Department Reports North Central Regions First Lab-Confirmed Flu Case of the Season
8. Cardium Reports on New York Citys Adoption of Therapeutic Cooling Protocols for Cardiac Arrest Patients
9. New Research Reports on Interventions that May Alter the Course of Epilepsy Diagnosis and Management
10. Cantel Medical Reports 72% Increase in Net Income on Record Sales - EPS of $0.20 vs. $0.12 for Quarter Ended October 31, 2008
11. MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Dublin - ... " Global Markets for Spectroscopy Equipment" report ... This report focuses on the global market of ... applications in various applications. The report deals with spectroscopy ... industries: pharmaceutical and biotechnology, food and beverage, and environmental ...
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
Breaking Medicine Technology: